Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of

Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial...

Related Keywords

Moorfields ,Ballymena ,United Kingdom ,United States ,London ,City Of ,American ,Jason Braco ,Michel Michaelides ,Botaretigene Sparoparvovec ,University College London ,Janssen Pharmaceuticals Inc ,Drug Administration ,American Academy Of Ophthalmology ,Janssen Pharmaceutical Companies Of Johnson ,Nasdaq ,American Academy Of Ophthalmology Annual Meeting ,Lifesci Communications ,Meiragtx Holdings ,Institute Of Ophthalmology ,European Medicines Agency ,Retina Subspecialty Day ,American Academy ,Professor Michel ,Alexandria Forbes ,Consultant Ophthalmologist ,Moorfields Eye Hospital ,Janssen Pharmaceuticals ,Janssen Pharmaceutical Companies ,Late Breaking Developments ,Gene Therapy Trial ,X Linked Retinitis Pigmentosa ,Fast Track ,Orphan Drug ,Advanced Therapy Medicinal Product ,Private Securities Litigation Reform Act ,Quarterly Report ,Ophthalmology Annual ,Nasdaq Mgtx ,Meiragtx ,